Literature DB >> 2460639

Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.

D Dowbenko1, G Nakamura, C Fennie, C Shimasaki, L Riddle, R Harris, T Gregory, L Lasky.   

Abstract

A soluble form of recombinant gp120 of human immunodeficiency virus type 1 was used as an immunogen for production of murine monoclonal antibodies. These monoclonal antibodies were characterized for their ability to block the interaction between gp120 and the acquired immunodeficiency syndrome virus receptor, CD4. Three of the monoclonal antibodies were found to inhibit this interaction, whereas the other antibodies were found to be ineffective at blocking binding. The gp120 epitopes which are recognized by these monoclonal antibodies were mapped by using a combination of Western blot (immunoblot) analysis of gp120 proteolytic fragments, immunoaffinity purification of fragments of gp120, and antibody screening of a random gp120 gene fragment expression library produced in the lambda gt11 expression system. Two monoclonal antibodies which blocked gp120-CD4 interaction were found to map to adjacent sites in the carboxy-terminal region of the glycoprotein, suggesting that this area is important in the interaction between gp120 and CD4. One nonblocking antibody was found to map to a position that was C terminal to this CD4 blocking region. Interestingly, the other nonblocking monoclonal antibodies were found to map either to a highly conserved region in the central part of the gp120 polypeptide or to a highly conserved region near the N terminus of the glycoprotein. N-terminal deletion mutants of the soluble envelope glycoprotein which lack these highly conserved domains but maintain the C-terminal CD4 interaction sites were unable to bind tightly to the CD4 receptor. These results suggest that although the N-terminal and central conserved domains of intact gp120 do not appear to be directly required for CD4 binding, they may contain information that allows other parts of the molecule to form the appropriate structure for CD4 interaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460639      PMCID: PMC253585     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

2.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

Review 3.  The differentiation and function of human T lymphocytes.

Authors:  E L Reinherz; S F Schlossman
Journal:  Cell       Date:  1980-04       Impact factor: 41.582

4.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

Authors:  F Barin; M F McLane; J S Allan; T H Lee; J E Groopman; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

5.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

6.  Dissection of Mycobacterium tuberculosis antigens using recombinant DNA.

Authors:  R A Young; B R Bloom; C M Grosskinsky; J Ivanyi; D Thomas; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

8.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

Authors:  D D Ho; J C Kaplan; I E Rackauskas; M E Gurney
Journal:  Science       Date:  1988-02-26       Impact factor: 47.728

10.  The epidemiology of AIDS: current status and future prospects.

Authors:  J W Curran; W M Morgan; A M Hardy; H W Jaffe; W W Darrow; W R Dowdle
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

View more
  27 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  The carboxy terminus of human immunodeficiency virus type 1 gp160 limits its proteolytic processing and transport in transfected cell lines.

Authors:  O K Haffar; G R Nakamura; P W Berman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding.

Authors:  A Cordonnier; Y Rivière; L Montagnier; M Emerman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

7.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Authors:  G R Nakamura; R Byrn; D M Wilkes; J A Fox; M R Hobbs; R Hastings; H C Wessling; M A Norcross; B M Fendly; P W Berman
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion.

Authors:  S R Pollard; W Meier; P Chow; J J Rosa; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4.

Authors:  W J Syu; J H Huang; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.